Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Euro Surveill ; 28(10)2023 03.
Article in English | MEDLINE | ID: mdl-36892470

ABSTRACT

BackgroundCarbapenemase-producing Enterobacterales (CPE) are rapidly increasing worldwide, also in Europe. Although prevalence of CPE in Germany is comparatively low, the National Reference Centre for Multidrug-resistant Gram-negative Bacteria noted annually increasing numbers of NDM-5-producing Escherichia coli isolates.AimAs part of our ongoing surveillance programme, we characterised NDM-5-producing E. coli isolates received between 2013 and 2019 using whole genome sequencing (WGS).MethodsFrom 329 identified NDM-5-producing E. coli, 224 isolates from known geographical locations were subjected to Illumina WGS. Analyses of 222 sequenced isolates included multilocus sequence typing (MLST), core genome (cg)MLST and single-nucleotide polymorphism (SNP)-based analyses.ResultsResults of cgMLST revealed genetically distinct clusters for many of the 43 detected sequence types (ST), of which ST167, ST410, ST405 and ST361 predominated. The SNP-based phylogenetic analyses combined with geographical information identified sporadic cases of nosocomial transmission on a small spatial scale. However, we identified large clusters corresponding to clonal dissemination of ST167, ST410, ST405 and ST361 strains in consecutive years in different regions in Germany.ConclusionOccurrence of NDM-5-producing E. coli rose in Germany, which was to a large extent due to the increased prevalence of isolates belonging to the international high-risk clones ST167, ST410, ST405 and ST361. Of particular concern is the supra-regional dissemination of these epidemic clones. Available information suggest community spread of NDM-5-producing E. coli in Germany, highlighting the importance of epidemiological investigation and an integrated surveillance system in the One Health framework.


Subject(s)
Escherichia coli Infections , Escherichia coli , Humans , Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Multilocus Sequence Typing , Phylogeny , beta-Lactamases/genetics , Germany/epidemiology , Microbial Sensitivity Tests , Clone Cells , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use
2.
Int J Med Microbiol ; 312(5): 151557, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35842996

ABSTRACT

OBJECTIVES: To report the detection of the class D carbapenemase OXA-181 in an MDR clinical Pseudomonas aeruginosa isolate in Germany. METHODS: Carbapenemase detection was performed by using several phenotypic tests such as the modified Hodge test, a combined disc test with boronic acid, EDTA or cloxacillin, a lysate-based inhibition assays and by PCR for common and rare carbapenemase genes. Antibiotic susceptibilities were determined by broth microdilution. The genetic environment of blaOXA-181 in the clinical P. aeruginosa isolate was characterised by Illumina and MinION sequencing. RESULTS: An multidrug-resistant P. aeruginosa was isolated from a tracheal swab in 2019 and was sent to the German National Reference Centre for multidrug-resistant Gram-negative bacteria for carbapenemase detection. Several phenotypic tests indicated the presence of a carbapenemase which was not inhibited by EDTA nor by boronic acid. PCRs for common and rare carbapenemase genes revealed the presence of a blaOXA-181 gene. WGS data confirmed that the gene was located on the chromosome as part of a Tn2013 transposon. The genetic organisation of blaOXA-181 has already been described in a P. aeruginosa isolate from England, but both isolates differed significantly in their sequence types (ST111/ST235). Analysis of the genetic environment of the blaOXA-181 gene also revealed high homology to a plasmid from a Klebsiella pneumoniae isolate. CONCLUSIONS: To our knowledge, this is the first report of blaOXA-181 in a clinical P. aeruginosa isolate in Germany which emphasises the ongoing spread of yet unusual carbapenemases among different Gram-negative species and therefore complicating their detection in routine laboratories.


Subject(s)
Anti-Bacterial Agents , Pseudomonas aeruginosa , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/analysis , Bacterial Proteins/genetics , Boronic Acids , Edetic Acid , Klebsiella pneumoniae/genetics , Microbial Sensitivity Tests , beta-Lactamases/analysis , beta-Lactamases/genetics
3.
J Antimicrob Chemother ; 77(5): 1247-1253, 2022 04 27.
Article in English | MEDLINE | ID: mdl-35257174

ABSTRACT

OBJECTIVES: To identify novel carbapenem resistance mechanisms and their potential to spread among clinical isolates. METHODS: Four clinical isolates of Citrobacter freundii, Serratia marcescens and Raoultella planticola (n = 2) from one hospital in Central Germany were sent to the German National Reference Centre for Multidrug-resistant Gram-negative Bacteria for carbapenemase detection. Phenotypic tests indicated the presence of a metallo-ß-lactamase (MBL), but PCR for various MBL genes could not identify any. Using WGS data, a putative bla gene was identified. Its carbapenemase activity was verified by heterologous expression in an Escherichia coli cloning strain, with subsequent MIC determination by broth microdilution, as well as by in vitro hydrolysis assays using purified enzyme. RESULTS: WGS indicated the presence of a putative ß-lactamase with 48% amino acid identity to the subclass B1 MBL SPM-1. MIC studies confirmed that the novel enzyme formed a functional MBL, which was therefore designated as GMB-1 (German MBL). In vitro hydrolysis assays showed a lack of activity not only against aztreonam but also against ertapenem. WGS revealed that in all three species the blaGMB-1 gene was located on the chromosome as part of a genetic island with multiple ISs. CONCLUSIONS: The finding of GMB-1 once again shows that novel carbapenemases continue to emerge and make their way into clinically relevant species. The occurrence of GMB-1 in three different species demonstrates the extraordinary mobility of such genetic islands and their potential to spread carbapenemase genes into diverse genetic environments.


Subject(s)
Anti-Bacterial Agents , beta-Lactamases , Anti-Bacterial Agents/pharmacology , Aztreonam , Escherichia coli , Microbial Sensitivity Tests , beta-Lactamases/metabolism
4.
J Antimicrob Chemother ; 75(4): 911-916, 2020 04 01.
Article in English | MEDLINE | ID: mdl-31960033

ABSTRACT

OBJECTIVES: To investigate the carbapenem resistance mechanism of a carbapenem-resistant clinical Pseudomonas aeruginosa isolate. METHODS: A carbapenem-resistant P. aeruginosa isolate was recovered from a tracheal swab from a patient of a general ward in central Germany. Various phenotypic tests confirmed production of a carbapenemase that could not be identified further by PCR. A novel bla gene was identified by WGS and its carbapenemase activity was verified by heterologous expression in an Escherichia coli cloning strain. Kinetic parameters of the novel ß-lactamase were determined by spectrophotometric measurements using purified enzyme. RESULTS: WGS confirmed the presence of a novel class A carbapenemase. The novel bla gene was named GPC-1 (GPC standing for German Pseudomonas Carbapenemase) and exhibited 77% amino acid identity to BKC-1. WGS also showed that blaGPC-1 was located on the chromosome surrounded by multiple ISs as part of a 26 kb genetic island. Heterologous expression of GPC-1 in E. coli TOP10 led to increased MICs of penicillins, oxyimino-cephalosporins, aztreonam and imipenem, but not of meropenem or ertapenem. Spectrophotometric measurements supported the MIC studies, but detected a slight hydrolysis of ertapenem and meropenem when using high concentrations of purified enzyme. CONCLUSIONS: The biochemical characterization of GPC-1 emphasizes the ongoing emergence of novel carbapenemases. Strains expressing a weak carbapenemase like GPC-1 might go unrecognized by routine diagnostics due to low MICs for the bacterial strains producing such enzymes.


Subject(s)
Escherichia coli , Pseudomonas aeruginosa , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Escherichia coli/genetics , Germany , Humans , Microbial Sensitivity Tests , Pseudomonas aeruginosa/genetics , beta-Lactamases/genetics
5.
J Antimicrob Chemother ; 74(10): 2891-2894, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31302698

ABSTRACT

OBJECTIVES: To characterize a new variant of the FRI class A carbapenemase isolated from an MDR clinical Enterobacter cloacae isolate. METHODS: A carbapenem-resistant E. cloacae was isolated from a rectal swab from a patient in an ICU in Southern Germany. Various phenotypic tests confirmed production of a putative class A carbapenemase. The new bla gene variant, blaFRI-3, and its genetic environment were characterized by WGS. Biochemical characterization was performed by heterologous expression in Escherichia coli TOP10 and by purification of the enzyme with subsequent determination of its kinetic parameters. RESULTS: PCR and sequencing carried out for different class A carbapenemase genes confirmed the presence of a novel variant of blaFRI-1. The novel variant was named FRI-3 and exhibited 91%, 96% and 92% amino acid identity to FRI-1, FRI-2 and FRI-4, respectively. E. coli TOP10 expressing blaFRI-3 showed increased resistance to almost all ß-lactams. Comparing the catalytic behaviour of FRI-3 and FRI-1, it was shown that FRI-3 had the same substrate spectrum, but basically hydrolysed ß-lactams less efficiently than FRI-1. WGS data revealed that blaFRI-3 was located on a 111 kb plasmid. CONCLUSIONS: The biochemical characterization of FRI-3 illustrates that even a few differences in the amino acid sequence can lead to altered catalytic activities of ß-lactamases belonging to the same family.


Subject(s)
Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Carbapenem-Resistant Enterobacteriaceae/enzymology , Enterobacter cloacae/enzymology , beta-Lactamases/genetics , beta-Lactamases/metabolism , Bacterial Proteins/classification , Bacteriological Techniques , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Carbapenems/metabolism , Enterobacter cloacae/isolation & purification , Enterobacteriaceae Infections/microbiology , Germany , Humans , Hydrolysis , Intensive Care Units , Polymerase Chain Reaction , Rectum/microbiology , Sequence Analysis, DNA , beta-Lactamases/classification
6.
Int J Syst Evol Microbiol ; 67(6): 1676-1682, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28141499

ABSTRACT

A novel strain, G25T, was isolated from desert soil collected near Jeddah in Saudi Arabia. The strain could accumulate nearly 65 % of its cell dry weight as fatty acids, grow on a broad range of carbon sources and tolerate temperatures of up to 50 °C. With respect to to its 16S rRNA gene sequence, G25T is most closely related to Streptomyces massasporeus DSM 40035T, Streptomyces hawaiiensis DSM 40042T, Streptomyces indiaensis DSM 43803T, Streptomyces luteogriseus DSM 40483T and Streptomyces purpurascens DSM 40310T. Conventional DNA-DNA hybridization (DDH) values ranged from 18.7 to 46.9 % when G25T was compared with these reference strains. Furthermore, digital DDH values between the draft genome sequence of G25T and the genome sequences of other species of the genus Streptomyces were also significantly below the threshold of 70 %. The DNA G+C content of the draft genome sequence, consisting of 8.46 Mbp, was 70.3 %. The prevalent cellular fatty acids of G25T comprised anteiso-C15 : 0, iso-C15 : 0, C16 : 0 and iso-C16 : 0. The predominant menaquinones were MK-9(H6), MK-9(H8) and MK-9(H4). The polar lipids profile contained diphosphatidylglycerol, phosphatidylethanolamine, phosphatidylinositol, phosphatidylglycerol and phosphatidylinositol mannosides as well as unidentified phospholipids and phosphoaminolipids. The cell wall contained ll-diaminopimelic acid. Whole-cell sugars were predominantly glucose with small traces of ribose and mannose. The results of the polyphasic approach confirmed that this isolate represents a novel species of the genus Streptomyces, for which the name Streptomyces jeddahensis sp. nov. is proposed. The type strain of this species is G25T (=DSM 101878T =LMG 29545T =NCCB 100603T).


Subject(s)
Phylogeny , Soil Microbiology , Streptomyces/classification , Bacterial Typing Techniques , Base Composition , DNA, Bacterial/genetics , Desert Climate , Diaminopimelic Acid/chemistry , Fatty Acids/chemistry , Nucleic Acid Hybridization , Phospholipids/chemistry , RNA, Ribosomal, 16S/genetics , Saudi Arabia , Sequence Analysis, DNA , Streptomyces/genetics , Streptomyces/isolation & purification , Vitamin K 2/analogs & derivatives , Vitamin K 2/chemistry
7.
Appl Environ Microbiol ; 82(19): 5969-81, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27474711

ABSTRACT

UNLABELLED: Recently, we isolated a novel Streptomyces strain which can accumulate extraordinarily large amounts of triacylglycerol (TAG) and consists of 64% fatty acids (dry weight) when cultivated with glucose and 50% fatty acids (dry weight) when cultivated with cellobiose. To identify putative gene products responsible for lipid storage and cellobiose utilization, we analyzed its draft genome sequence. A single gene encoding a wax ester synthase/acyl coenzyme A (CoA):diacylglycerol acyltransferase (WS/DGAT) was identified and heterologously expressed in Escherichia coli The purified enzyme AtfG25 showed acyltransferase activity with C12- or C16-acyl-CoA, C12 to C18 alcohols, or dipalmitoyl glycerol. This acyltransferase exhibits 24% amino acid identity to the model enzyme AtfA from Acinetobacter baylyi but has high sequence similarities to WS/DGATs from other Streptomyces species. To investigate the impact of AtfG25 on lipid accumulation, the respective gene, atfG25, was inactivated in Streptomyces sp. strain G25. However, cells of the insertion mutant still exhibited DGAT activity and were able to store TAG, albeit in lower quantities and at lower rates than the wild-type strain. These findings clearly indicate that AtfG25 has an important, but not exclusive, role in TAG biosynthesis in the novel Streptomyces isolate and suggest the presence of alternative metabolic pathways for lipid accumulation which are discussed in the present study. IMPORTANCE: A novel Streptomyces strain was isolated from desert soil, which represents an extreme environment with high temperatures, frequent drought, and nutrient scarcity. We believe that these harsh conditions promoted the development of the capacity for this strain to accumulate extraordinarily large amounts of lipids. In this study, we present the analysis of its draft genome sequence with a special focus on enzymes potentially involved in its lipid storage. Furthermore, the activity and importance of the detected acyltransferase were studied. As discussed in this paper, and in contrast to many other bacteria, streptomycetes seem to possess a complex metabolic network to synthesize lipids, whereof crucial steps are still largely unknown. This paper therefore provides insights into a range of topics, including extremophile bacteria, the physiology of lipid accumulation, and the biotechnological production of bacterial lipids.


Subject(s)
Acyl Coenzyme A/genetics , Bacterial Proteins/genetics , Diacylglycerol O-Acyltransferase/genetics , Genome, Bacterial , Streptomyces/genetics , Acyl Coenzyme A/metabolism , Bacterial Proteins/metabolism , Diacylglycerol O-Acyltransferase/metabolism , Esters/metabolism , Sequence Analysis, DNA , Streptomyces/metabolism , Transcriptome
8.
J Am Pharm Assoc (2003) ; 53(5): 488-95, 2013.
Article in English | MEDLINE | ID: mdl-24030126

ABSTRACT

OBJECTIVE: To examine parents' experience with the process of obtaining the influenza vaccine and their perceptions about pharmacists providing influenza vaccination services to their children. DESIGN: Cross-sectional descriptive study. SETTING: Wisconsin between November 2011 and April 2012. PARTICIPANTS: Children receiving an influenza vaccination from a Unity Health Insurance (UHI)-covered pharmacy between September and December 2011 were identified from pharmacy claims data, and parents of the children were sent a letter requesting their participation in the study. INTERVENTION: Online survey. MAIN OUTCOME MEASURES: Parents' experience with the process of obtaining the influenza vaccine and their perceptions about pharmacists providing influenza vaccinations to their children. RESULTS: 179 parents received a letter from UHI requesting their participation in the study, and the usable response rate for the study was 48%. Parents' experience with the process of obtaining the influenza vaccine was positive. A majority of parents did not need an appointment (98%) and visited a pharmacy during the hours of 3:05 pm to 6:00 pm (51%). Approximately 97% of the responding parents felt confident about the pharmacist providing influenza vaccinations to their children. CONCLUSION: Parents appear to be willing to accept pharmacists as an immunization resource for their children.


Subject(s)
Influenza Vaccines/administration & dosage , Parents/psychology , Pharmaceutical Services/organization & administration , Pharmacists/organization & administration , Adolescent , Adult , Child , Cross-Sectional Studies , Data Collection , Female , Humans , Male , Middle Aged , Professional Role , Wisconsin
SELECTION OF CITATIONS
SEARCH DETAIL
...